Effectiveness and Safety of Upadacitinib in Adolescent and Adult Patients with Atopic Dermatitis: An Analysis of Short-Term (Week 8-20) Data from a Real-World Multicenter Retrospective Review

被引：1
作者：
Rankin, Brian D. [1 ]
Sood, Siddhartha [2 ]
Park, Ye-Jean [2 ]
Rimke, Alexander [3 ]
Abduelmula, Abrahim [4 ]
Georgakopoulos, Jorge R. [4 ]
Leung, Fernejoy [3 ,5 ]
Stark, Lauren A. [3 ,5 ]
Devani, Alim R. [3 ,5 ,6 ]
Yeung, Jensen [4 ,6 ,7 ,8 ]
Prajapati, Vimal H. [1 ,3 ,5 ,6 ,9 ,10 ]
机构：
[1] Univ Calgary, Dept Med, Div Dermatol, Calgary, AB, Canada
[2] Univ Toronto, Temerty Fac Med, Toronto, ON, Canada
[3] Dermatol Res Inst, Calgary, AB, Canada
[4] Univ Toronto, Dept Med, Div Dermatol, Toronto, ON, Canada
[5] Skin Hlth & Wellness Ctr, Calgary, AB, Canada
[6] Prob Med Res, Waterloo, ON, Canada
[7] Womens Coll Hosp, Dept Med, Div Dermatol, Toronto, ON, Canada
[8] Sunnybrook Hlth Sci Ctr, Dept Med, Div Dermatol, Toronto, ON, Canada
[9] Univ Calgary, Dept Pediat, Sect Community Pediat, Calgary, AB, Canada
[10] Univ Calgary, Dept Pediat, Sect Pediat Rheumatol, Calgary, AB, Canada
来源：
DERMATITIS | 2024年
关键词：
DOUBLE-BLIND; PLACEBO;
D O I：
10.1089/derm.2024.0097
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
引用
收藏
页数：3
相关论文
共 5 条
  • [1] Chiricozzi A, 2023, AM J CLIN DERMATOL, V24, P963, DOI 10.1007/s40257-023-00813-4
  • [2] Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double- blind, randomised controlled phase 3 trials
    Guttman-Yassky, Emma
    Teixeira, Henrique D.
    Simpson, Eric L.
    Papp, Kim A.
    Pangan, Aileen L.
    Blauvelt, Andrew
    Thaci, Diamant
    Chu, Chia-Yu
    Hong, H. Chih-Ho
    Katoh, Norito
    Paller, Amy S.
    Calimlim, Brian
    Gu, Yihua
    Hu, Xiaofei
    Liu, Meng
    Yang, Yang
    Liu, John
    Tenorio, Allan R.
    Chu, Alvina D.
    Irvine, Alan D.
    [J]. LANCET, 2021, 397 (10290) : 2151 - 2168
  • [3] Upadacitinib in adults with moderate to severe atopic dermatitis: 16-week results from a randomized, placebo-controlled trial
    Guttman-Yassky, Emma
    Thaci, Diamant
    Pangan, Aileen L.
    Hong, H. Chih-ho
    Papp, Kim A.
    Reich, Kristian
    Beck, Lisa A.
    Mohamed, Mohamed-Eslam F.
    Othman, Ahmed A.
    Anderson, Jaclyn K.
    Gu, Yihua
    Teixeira, Henrique D.
    Silverberg, Jonathan I.
    [J]. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2020, 145 (03) : 877 - 884
  • [4] Drug Survival of Upadacitinib and Predicting Factors of Discontinuation in Adult Patients Affected by Moderate-to-Severe Atopic Dermatitis: An Italian Multicenter Analysis
    Pezzolo, Elena
    Ortoncelli, Michela
    Ferrucci, Silvia Mariel
    Guanti, Mario Bruno
    Schena, Donatella
    Napolitano, Maddalena
    Rossi, Mariateresa
    Foti, Caterina
    D'Amico, Domenico
    Amoruso, Giuseppe Fabrizio
    Morrone, Pietro
    Ribero, Simone
    Barei, Francesca
    Biagi, Matteo
    Pascucci, Enrico
    Patruno, Cataldo
    Pinton, Piergiacomo Calzavara
    Romita, Paolo
    Gargiulo, Luigi
    Narcisi, Alessandra
    Naldi, Luigi
    [J]. JOURNAL OF CLINICAL MEDICINE, 2024, 13 (02)
  • [5] Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis (AD Up): results from a randomised, double-blind, placebo-controlled, phase 3 trial
    Reich, Kristian
    Teixeira, Henrique D.
    de Bruin-Weller, Marjolein
    Bieber, Thomas
    Soong, Weily
    Kabashima, Kenji
    Werfel, Thomas
    Zeng, Jiewei
    Huang, Xiaohong
    Hu, Xiaofei
    Hendrickson, Barbara A.
    Ladizinski, Barry
    Chu, Alvina D.
    Silverberg, Jonathan I.
    [J]. LANCET, 2021, 397 (10290) : 2169 - 2181
1